Goldberg Itzhak
Known title: See RemarksCIK: 0001607858
Associated companies
Transaction History
| ELTX | ▼ Sell | Tax Withholding | 32,082 | $36K | 7/1/2022 | View on chart |
| ELTX | ▼ Sell | Open Market | 32,118 | $108K | 12/6/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 40,215 | $136K | 12/3/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 38,800 | $136K | 12/2/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 38,867 | $138K | 12/1/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 38,495 | $164K | 11/16/2021 | View on chart |
| ELTX | ▼ Sell | Open Market | 111,505 | $465K | 11/15/2021 | View on chart |
| ELTX | ▼ Sell | Tax Withholding | 47,410 | $653K | 6/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target
Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.